Provided by Tiger Fintech (Singapore) Pte. Ltd.

INCANNEX HEALTHCARE LTD

1.05
-0.5800-35.58%
Post-market: 1.100.0502+4.78%19:59 EDT
Volume:222.65M
Turnover:244.81M
Market Cap:98.38M
PE:-0.87
High:1.27
Open:0.9837
Low:0.9500
Close:1.63
Loading ...

Incannex Healthcare Inc. Appoints Dr. Charlene E. Gamaldo to Clinical Advisory Board for Obstructive Sleep Apnea Program

Reuters
·
Yesterday

BRIEF-Incannex Healthcare Inc Files For Common Stock Offering Of Up To $100 Million - SEC Filing

Reuters
·
Yesterday

Incannex Healthcare Expands "At-The-Market" Offering Capacity by $100 Million to Enhance Financial Flexibility

Reuters
·
Yesterday

Incannex Healthcare Inc Files for Common Stock Offering of up to $100 Mln - SEC Filing

THOMSON REUTERS
·
Yesterday

Press Release: Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Dow Jones
·
24 Jun

Incannex Healthcare Achieves Key Milestone with Phase 2 Trial Database Lock for First-in-Class OSA Drug, Top-Line Results Expected July 2025

Reuters
·
18 Jun

Incannex Healthcare and Mind Medicine Australia Launch Joint Venture for Psychedelic-Assisted Therapy Clinic in Melbourne

Reuters
·
17 Jun

Incannex Healthcare Inc. Initiates Transfer of Listing to Nasdaq Capital Market to Meet Compliance Requirements

Reuters
·
13 Jun

Incannex cancels all outstanding Series A warrants following ATM execution

TIPRANKS
·
12 Jun

Incannex Healthcare Streamlines Capital Structure, Cancels Series A Warrants Ahead of Key Phase 2 Trial Milestone for IHL-42X in Obstructive Sleep Apnea

Reuters
·
12 Jun

Press Release: Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

Dow Jones
·
03 Jun

Incannex Healthcare Inc. Advances to Phase 3 Clinical Trial for IHL-42X in Obstructive Sleep Apnea Treatment, Following FDA Authorization

Reuters
·
29 May

BRIEF-Incannex Healthcare Advances IHL-42X Reposa Trial To Phase 3 Following FDA Protocol Clearance

Reuters
·
29 May

Stonegate Capital Partners Updates Coverage on Incannex Healthcare, Highlights Cost Savings and Financial Improvements

Reuters
·
29 May

Incannex Healthcare Cancels Series A Warrants, Eliminates Potential Dilution of 347 Million Shares Ahead of Key Trial Results

Reuters
·
28 May

Incannex Healthcare Inc. Expands Share Issuance Program with Amended Sales Agreement, Adds $50 Million in Common Stock

Reuters
·
28 May

Incannex Healthcare Announces Strategic Warrant Cancellation to Reduce Potential Dilution and Enhance Shareholder Value

Reuters
·
20 May

Incannex Healthcare Inc. Expands Share Issuance Agreement to $2.5 Million Under Sales Agreement with A.G.P/Alliance Global Partners

Reuters
·
20 May

Incannex Healthcare Announces Potential 50% Reduction in Series A Warrants to Minimize Stockholder Dilution

Reuters
·
16 May

Incannex Healthcare Inc. Announces New Agreement with Warrant Holders, Reducing Series A Warrants in Exchange for Up to $12.5 Million in Net Proceeds

Reuters
·
16 May